Evidence map›Paper›PMID 34999110›Full record

ArticleMicrovascular research2022

Gene therapy with Pellino-1 improves perfusion and decreases tissue loss in Flk-1 heterozygous mice but fails in MAPKAP Kinase-2 knockout murine hind limb ischemia model.

Mahesh Thirunavukkarasu, Seetur R Pradeep, Gopi Ukani, Salim Abunnaja, Mark Youssef, Diego Accorsi, Santosh Swaminathan, Sue Ting Lim, Virginia Parker, Jacob Campbell and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microvascular research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Mahesh ThirunavukkarasuMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA.
Seetur R PradeepMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA.
Gopi UkaniMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA; Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA.
Salim AbunnajaMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA; Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA.
Mark YoussefMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA; Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA.
Diego AccorsiMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA; Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA.
Santosh SwaminathanMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA; Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA.
Sue Ting LimMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA; Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA.
Virginia ParkerMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA; Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA.
Jacob CampbellMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA.
Muhammad Tipu RishiMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA; Stanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA.
J Alexander PalestyStanley J. Dudrick, Department of Surgery, Saint Mary's Hospital, Waterbury 06706, CT, USA.
Nilanjana MaulikMolecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut School of Medicine, University of Connecticut Health Center, Farmington 06030, CT, USA. Electronic address: nmaulik@uchc.edu.
UConn Health · US

Funding

Angiogenic Regulators in Ischemic DisordersR01GM112957 · NIGMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI MAULIK, NILANJANA · 2015 to 2018
$1.7M
NIGMS NIH HHS R01 GM112957
6 · The paper itself

Abstract

objectivesIn the United States, over 8.5 million people suffer from peripheral arterial disease (PAD). Previously we reported that Pellino-1(Peli1) gene therapy reduces ischemic damage in the myocardium and skin flaps in Flk-1 [Fetal Liver kinase receptor-1 (Flk-1)/ Vascular endothelial growth factor receptor-2/VEGFR2] heterozygous (Flk-1 STUDY DESIGN AND

methodsFemoral artery ligation (HLI) was performed in both Flk-1

resultsFlk-1

conclusionDeletion of Flk-1 and MK2 impairs neovascularization and perfusion following HLI. Treatment with Ad. Peli1 results in increased angiogenesis and improved perfusion in Flk-1

Indexed as

Peripheral Arterial DiseaseVascular Endothelial Growth Factor Receptor-2AnimalsDisease Models, AnimalFibrosisGenetic TherapyHindlimbHumansIntracellular Signaling Peptides and ProteinsIschemiaMAP-Kinase-Activated Kinase 2MiceMice, Inbred C57BLMice, KnockoutNeovascularization, PhysiologicNuclear ProteinsIntracellular Signaling Peptides and ProteinsMAP-Kinase-Activated Kinase 2Nuclear ProteinsPeli1 protein, mouseProtein Serine-Threonine KinasesUbiquitin-Protein LigasesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Hind limb ischemiaIschemic scorePeli1PerfusionVEGF signaling

Identifiers

PMID34999110
PMCPMC9250804
OpenAlexW4205611614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.